Survivin as a biological biomarker for diagnosis and therapy
Yuming Li, Wenshu Lu, Jiarun Yang, Mark Edwards, Shisong Jiang
Abstract
: The most promising developments involve anti-SVN immunotherapy, with several therapeutic SVN vaccines under evaluation in phase I/II trials. SVN is an important new immune-oncology target that expands the repertoire of individualized combination treatments for cancer.
Topics & Concepts
MedicineImmunotherapyBiomarkerSurvivinClinical trialCancerTargeted therapyBiomarker discoveryImmunologyOncologyCancer researchImmune systemInternal medicineProteomicsBiologyGeneBiochemistryCell death mechanisms and regulationImmunotherapy and Immune Responsesinterferon and immune responses